Myrexis Presents Data on Cancer Metabolism Inhibitor at 22nd EORTC/NCI/AACR Symposium

SALT LAKE CITY, Nov. 17, 2010 (GLOBE NEWSWIRE) — Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on “Molecular [...] http://bit.ly/9CKeVH